Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Decline in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 500 shares, a decline of 87.8% from the May 31st total of 4,100 shares. Based on an average daily trading volume, of 290,100 shares, the days-to-cover ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Down 6.6 %

PVCT stock traded down $0.01 during trading on Friday, reaching $0.13. The stock had a trading volume of 319,198 shares, compared to its average volume of 112,411. The stock’s 50 day moving average is $0.18 and its two-hundred day moving average is $0.15. Provectus Biopharmaceuticals has a 52 week low of $0.06 and a 52 week high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.